<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-07-14">14 July 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Chiara</forename><surname>De-Colle</surname></persName>
							<email>chiara.de-colle@med.uni-tuebingen.de</email>
							<affiliation key="aff0">
								<orgName type="department">Radiation Oncology, Medical Faculty and University Hospital</orgName>
								<orgName type="institution">Eberhard Karls University Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Mönnich</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Radiation Oncology, Medical Faculty and University Hospital</orgName>
								<orgName type="institution">Eberhard Karls University Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="department" key="dep2">Heidelberg and German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Welz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Radiation Oncology, Medical Faculty and University Hospital</orgName>
								<orgName type="institution">Eberhard Karls University Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Simon</forename><surname>Boeke</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Radiation Oncology, Medical Faculty and University Hospital</orgName>
								<orgName type="institution">Eberhard Karls University Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bence</forename><surname>Sipos</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Pathology, Medical Faculty and University Hospital</orgName>
								<orgName type="institution">Eberhard Karls University Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Falko</forename><surname>Fend</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Pathology, Medical Faculty and University Hospital</orgName>
								<orgName type="institution">Eberhard Karls University Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul-Stefan</forename><surname>Mauz</surname></persName>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Department of Otorhinolaryngology, Head and Neck Surgery</orgName>
								<orgName type="department" key="dep2">Medical Faculty and University Hospital</orgName>
								<orgName type="institution">Eberhard Karls University Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Inge</forename><surname>Tinhofer</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">Department of Radiooncology and Radiotherapy</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Volker</forename><surname>Budach</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department">Department of Radiooncology and Radiotherapy</orgName>
								<orgName type="institution">Charité University Hospital</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Abu</forename><surname>Jawad</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Department of Radiotherapy</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Stuschke</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Department of Radiotherapy</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">University of Duisburg-Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Panagiotis</forename><surname>Balermpas</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Department of Radiotherapy and Oncology</orgName>
								<orgName type="institution">Goethe-University</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claus</forename><surname>Rödel</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="department">Department of Radiotherapy and Oncology</orgName>
								<orgName type="institution">Goethe-University</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anca-Ligia</forename><surname>Grosu</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Freiburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="department">Department of Radiation Oncology</orgName>
								<orgName type="institution">University of Freiburg</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Amir</forename><surname>Abdollahi</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Heidelberg Institute of Radiation Oncology (HIRO)</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">National Center for Radiation Research in Oncology (NCRO)</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department" key="dep1">Heidelberg Ion Therapy Center (HIT)</orgName>
								<orgName type="department" key="dep2">Department of Radiation Oncology</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">National Center for Tumor Diseases (NCT)</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="department" key="dep1">Translational Radiation Oncology</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jürgen</forename><surname>Debus</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Heidelberg Institute of Radiation Oncology (HIRO)</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">National Center for Radiation Research in Oncology (NCRO)</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department" key="dep1">Heidelberg Ion Therapy Center (HIT)</orgName>
								<orgName type="department" key="dep2">Department of Radiation Oncology</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">National Center for Tumor Diseases (NCT)</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="laboratory">Clinical Cooperation Unit Radiation Oncology</orgName>
								<orgName type="institution">University of Heidelberg Medical School</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><surname>Bayer</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claus</forename><surname>Belka</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">Department of Radiotherapy and Radiation Oncology</orgName>
								<orgName type="institution">Ludwig-Maximilians-Universität</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Steffi</forename><surname>Pigorsch</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Institute for Innovative Radiation Therapy in Helmholtz-Zentrum München</orgName>
								<orgName type="institution">Technische Universität München</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephanie</forename><forename type="middle">E</forename><surname>Combs</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Institute for Innovative Radiation Therapy in Helmholtz-Zentrum München</orgName>
								<orgName type="institution">Technische Universität München</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fabian</forename><surname>Lohaus</surname></persName>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Heidelberg, Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">Department of Radiotherapy and Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technische Universität Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff23">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">OncoRay -National Center for Radiation Research in Oncology</orgName>
								<orgName type="institution" key="instit2">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit3">Technische Universität Dresden</orgName>
								<orgName type="institution" key="instit4">Helmholtz-Zentrum Dresden-Rossendorf</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="department">National Center for Tumor Diseases (NCT)</orgName>
								<address>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff25">
								<orgName type="department" key="dep1">Institute of Radiooncology -OncoRay</orgName>
								<orgName type="department" key="dep2">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">Helmholtz-Zentrum Dresden-Rossendorf</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country>Germany aa, Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff26">
								<orgName type="department">Radiation Oncology</orgName>
								<orgName type="institution">University Hospital Tübingen</orgName>
								<address>
									<addrLine>Hoppe-Seyler-Str. 3</addrLine>
									<postCode>72076</postCode>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-07-14">14 July 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">5FE066D211406FB9638620C3379484C2</idno>
					<idno type="DOI">10.1016/j.ctro.2017.06.004</idno>
					<note type="submission">Received 4 May 2017 Revised 6 June 2017 Accepted 10 June 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:51+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>SDF-1 CXCR4 Head and neck cancer</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Introduction: Outcome after postoperative radiochemotherapy (RT-CT) for patients with advanced head and neck squamous cell carcinomas (HNSCC) remains unsatisfactory, especially among those with HPV negative tumours.</s><s>Therefore, new biomarkers are needed to further define subgroups for individualised therapeutic approaches.</s><s>Preclinical and first clinical observations showed that the chemokine receptor CXCR4 and its ligand SDF-1 (CXCL12) play an important role in tumour cell proliferation, survival, cancer progression, metastasis and treatment resistance.</s><s>However, the data on the prognostic value of SDF-1/ CXCR4 expression for HNSCC are conflicting.</s><s>The aim of our hypothesis-generating study was to retrospectively explore the prognostic potential of SDF-1/CXCR4 in a well-defined cohort of HNSCC patients collected within the multicenter biomarker study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Head and neck squamous cell carcinomas (HNSCC) represent about 5% of the newly world-wide diagnosed tumours <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>Radiotherapy (RT) is a corner stone of the HNSCC treatment and often performed in combination with chemotherapy (CT) either in a primary setting or as adjuvant therapy following surgery.</s><s>Based on randomized studies that showed a benefit by adding CT to RT, high risk resected locally advanced HNSCC are currently commonly treated with adjuvant RT-CT, with a 5-years overall survival (OS) of about 50% <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>.</s><s>In a previous publication <ref type="bibr" target="#b5">[6]</ref> the Radiation Oncology Group of the German Cancer Consortium (DKTK-ROG) demonstrated that HPV16 DNA status is a strong prognostic factor for loco-regional control (LRC) for locally advanced HNSCC treated with surgery and adjuvant RT-CT.</s><s>The LRC in patients with HPV16 DNA positive tumours was close to 100%, while the rate of locoregional relapse among those with HPV negative tumours reached 20%.</s><s>Therefore, biomarkers are needed, which help to identify patients with HPV negative tumours who are on high risk of relapse in order to subject them for treatment intensification, e.g., by molecular targeting, radiation dose escalation or hypoxia modification.</s><s>Chemokines are emerging as potential biomarkers and molecular targets to overcome treatment resistance in several types of cancer including HNSCC <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref>.</s></p><p><s>Chemokines are small cytokines that bind to trans-membrane domain of G-protein-coupled receptors.</s><s>They are responsible for leucocyte trafficking and homing and were shown to be involved in tumour development and progress.</s><s>Particularly, CXCR4 together with its ligand SDF-1 (stromal derived factor 1, also called CXCL12) were reported to influence cell survival, proliferation and migration.</s><s>They can interfere directly with intracellular signalling pathways such as MAPK and PI3K/AKT or promote angiogenesis, stimulate interleukins or recruit myeloid bone marrow-derived tumour-promoting cells to the tumour site <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>.</s><s>Moreover, a higher CXCR4 expression was observed in the CD44 positive tumours cell fraction from tumour cell lines and patient-derived tumour tissue, indicating a key role of SDF-1/CXCR4 pathway in tumour aggressiveness and resistance to treatment strategies <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>.</s><s>Studies conducted on HNSCC cell lines or in HNSCC nude mice models showed that SDF-1/CXCR4 expression enhances cell motility, proliferation and metastases via up-regulation of ERK1/2, AKT/PKB, PI3K-AKT, NF-kB and matrix metalloproteinases (MMP) <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref>.</s><s>Some clinical data suggest higher metastatic potential and worse outcomes in patients with SDF-1/CXCR4 positive HNSCC tumours <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref>.</s><s>However, the existing clinical evidence is partly conflicting, limited due to the small number of patients and the large heterogeneity in SDF-1/CXCR4 detection methods, patient and tumour characteristics, applied treatments and reported outcome parameters.</s><s>In the present retrospective study, we aimed to explore the prognostic potential of SDF-1/ CXCR4 expression in a well-defined large cohort of patients with locally advanced high-risk HNSCC treated with surgery and adjuvant CT-RT as part of a multicentre biomarker trial conducted by the DKTK-ROG.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and treatment</head><p><s>The trial was approved by the ethical committees of all the DKTK-ROG centres.</s><s>The eligibility criteria, along with the clinical characteristics and treatments details were previously described <ref type="bibr" target="#b5">[6]</ref>.</s><s>Briefly, 221 patients with locally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx treated between 2004 and 2012 with surgery and adjuvant RT-CT were included in the study.</s><s>All patients had received platinum-based CT (median dose 200 mg/m 2 ) and RT consisting of a median dose of 50.4 Gy elective nodal irradiation with a boost up to a median dose of 64 Gy to the former tumour region.</s><s>All patients had one or more of the following high-risk factors: stage pT4, &gt;3 positive lymph nodes, positive microscopic resection margins, extracapsular extension.</s><s>Clinical information, RT treatment plans and follow up data were collected and evaluated centrally at the DKTK partner site Dresden.</s><s>In addition, a central radiological review of the imaging of relapses was performed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tissue samples</head><p><s>Formalin-fixed paraffin-embedded (FFPE) materials of primary tumour specimens retrieved after surgery were collected and centrally processed at the DKTK partner site Dresden.</s><s>All the samples were stained with haematoxylin and eosin for histology verification.</s><s>Tissue microarrays (TMAs, 1-mm diameter each core) were generated, and the tumour content in each TMA core was reviewed by expert pathologists.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HPV16 DNA and p16 evaluation</head><p><s>Methods used for the determination of HPV16 DNA and p16 were previously described <ref type="bibr" target="#b5">[6]</ref>.</s><s>Briefly, HPV DNA was extracted from FFPE-sections, amplified by PCR and detected by hybridisation using QIAamp DNA FFPE tissue kit (Qiagen GmbH, Hilden, Germany), HotStarTaq Plus Master Mix (Qiagen GmbH) and LCD-Array HPV 3.5 kit (CHIPRON GmbH, Berlin, Germany), respectively, according to the manufacturer's instruction.</s><s>Samples from 6 patients were excluded because of insufficient DNA.</s><s>Immunohistochemical staining of p16 was performed using the CINtec Histology Kit (Roche mtm laboratories AG, Basel, CH), according to the manufacturer's instruction.</s><s>Tumour samples expressing p16 in !70% were considered positive (overexpression).</s><s>7 patients had to be excluded because of insufficient tumour material (&lt;10%) in the FFPE samples.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Staining, imaging and scoring system</head><p><s>TMAs were stained for SDF-1 and CXCR4 using immunofluorescence.</s><s>Under supervision of an experienced pathologist (BS), SDF-1 and CXCR4 staining was established using positive (tonsil tissue) and negative controls (no primary antibody and anti-IgG from the same specie).</s><s>After deparaffinization, rehydration and epitope-retrieval technique, sections were stained with TSATM Kit T20912 (containing goat anti-mouse IgG and tyramide labelled with Alexa 488, Life Technologies GmbH, Molecular probes, Invitrogen, Darmstadt, Germany) for SDF-1 detection and with TSATM Kit T20922 (containing goat anti-rabbit IgG and tyramide labelled with Alexa 488, Life Technologies GmbH, Molecular probes, Invitrogen, Darmstadt, Germany) for CXCR4 detection, according to the manufactures instructions.</s><s>An antibody dilution of 1:100 was used for SDF-1 (mouse monoclonal, Clone 79018, R&amp;D Systems, Minneapolis, USA; dilution 1:100) and of 1:200 for CXCR4 (rabbit monoclonal [UMB2], Clone ab124824, Abcam, Cambridge Science Park Milton Rd, Milton, Cambridge, United Kingdom; dilution 1:200).</s><s>Imaging of the TMAs was performed using a Zeiss Axio Imager MI fluorescence microscope controlled by AxioVision 4.8 software (Carl Zeiss, Jena, Germany).</s><s>Whole TMA scans were performed using a motorised scanning stage and a monochrome digital camera (AxioCam MRm, Carl Zeiss, Jena, Germany; Maerzhaeuser, Wetzlar, Germany, 400Â (EC Plan Neofluar)).</s><s>Different specific staining patterns, i.e., membrane and intracellular (including cytoplasmic and nuclear), could be observed and were confirmed by an expert pathologist (BS).</s><s>The staining extent and intensity were evaluated only in the tumour areas.</s><s>The staining intensity was scored semi-quantitatively with arbitrary thresholds per each core from 0 to 3 as follow: negative (0), low (1), intermediate (2) and high <ref type="bibr" target="#b2">(3)</ref>.</s><s>The score per each pattern type was calculated as the mean score of all the cores of the tumour specimen derived from each patient.</s><s>At least one core having a score !2 (meaning a mean patient score &gt;1) was considered as positive.</s><s>This semi-quantitative analysis of the tissue staining was performed blinded to the clinical characteristics and oncological outcome of the patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistics</head><p><s>Loco-regional tumour control (LRC), distant metastasis free survival (DMFS) and overall survival (OS) defined as event from the date of RT-CT start were calculated and Kaplan-Meier curves generated.</s><s>Comparisons between staining results and clinicopathological data were performed using the Fisher's exact test.</s><s>Prognostic parameters were evaluated using univariate and multivariate analysis (Cox proportional hazard model).</s><s>Hazard ratios and 95% confidence intervals were calculated.</s><s>p-values &lt; 0.05 were considered statistically significant and p-values between 0.05 and 0.1 were considered as a trend.</s><s>No correction for multiple testing was performed.</s><s>Analyses were performed using the open-source software R (version 3.2.3</s><s>www.r-project.org).</s><s>Graphical representation was performed using GraphPad Prism version 7 for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>A total of 221 patients from 8 different DKTK partner sites with a median follow-up of 47.3 months (range, 2.5-100 months) were included in this retrospective biomarker study.</s><s>The details of the entire study population and treatment have been previously published <ref type="bibr" target="#b5">[6]</ref>.</s><s>For the present study, TMA including one up to five cores from tumour specimens of 201 of these patients were available for SDF-1 and 190 for CXCR4 staining.</s><s>The characteristics of this patient subgroup are summarised in Table <ref type="table" target="#tab_0">1</ref>.</s><s>SDF-1 and CXCR4 showed a heterogeneous staining pattern between the tumours of different patients and within the cancer cells, i.e., a membranous and intracellular staining (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Based on the semi-quantitative criteria membranous expression of SDF-1 (mSDF-1) and CXCR4 (mCXCR4) was detected in tumours of 24 (11.9%) and 14 (7%) patients, respectively.</s><s>The intracellular expression of SDF-1 (icSDF-1) and CXCR4 (icCXCR4) was found to be positive in tumours of 53 (26.4%) and 55 patients (27.4%), respectively (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The distribution of icSDF-1 and icCXCR4 expression in relation to clinical and pathological characteristics are summarised in Table <ref type="table" target="#tab_1">2</ref>, indicating significantly higher proportion of icSDF-1 expression among histological grade 2 (G2), HPV16 DNA and p16 positive tumours.</s><s>icCXCR4 staining was associated with histological G2 and lower pT-stages.</s></p><p><s>Neither mSDF-1 nor mCXCR4 expression was associated with LRC, DMFS or OS (Table <ref type="table" target="#tab_2">3</ref>).</s><s>LRC rates were significantly lower in icSDF-1 positive tumours in the entire cohort and in the HPV16 DNA positive subgroup (Fig. <ref type="figure" target="#fig_1">2</ref>).</s><s>As a trend, higher icCXCR4 expression was associated with lower LRC (Fig. <ref type="figure" target="#fig_1">2</ref>).</s><s>In the univariate analysis of the entire cohort and the subgroup of patients with HPV16 DNA negative tumours icSDF-1 expression was associated with significantly lower LRC (HR 2.67, 95% CI 1.29-5.54</s><s>and HR 2.54, 1.19-5.4,</s><s>respectively) but without association with DMFS or OS (Table <ref type="table" target="#tab_2">3</ref>).</s><s>IcCXCR4 expression showed a trend towards lower LRC.</s><s>The combined expression, i.e., tumours positive for icSDF-1 and icCXCR4 versus all other, was significantly associated with lower LRC.</s><s>No significant heterogeneity of the effect was observed between the different centres (data not shown).</s><s>The multivariate analysis revealed an independent negative prognostic value of icSDF-1 for LRC in the entire patient cohort and in the subgroup of patients with HPV16 DNA negative tumours (Table <ref type="table" target="#tab_3">4</ref>).</s><s>CXCR4 was not significantly associated with LRC.</s><s>The combined parameter of SDF-1/CXCR4 expression did not outperform SDF-1 expression alone.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The present exploratory study suggests that SDF-1 expression in tumours is an independent negative prognostic marker for LRC after postoperative RT-CT that might stratify patients with highrisk HPV negative HNSCC for treatment modification.</s><s>CXCR4 showed a trend in univariate analysis but was not prognostic in multivariate analysis.</s><s>To our knowledge, this is the largest biomarker study in a patient population with locally advanced HNSCC who received postoperative RT-CT.</s><s>Our data suggest a role of SDF-1 for resistance to postoperative RT-CT.</s></p><p><s>Signalling via the SDF-1/CXCR4 axis is well established as a chemokine-receptor pathway playing an important role in cancer progression and malignancy.</s><s>Tumour infiltrating leukocytes but also fibroblasts, endothelial and especially tumour epithelial cells are able to produce chemokines and express chemokine receptors, determining a chemokine gradient and network that influence tumour cell growth, survival and migration <ref type="bibr" target="#b8">[9]</ref>.</s><s>The autocrine and paracrine actions of SDF-1 on CXCR4-expressing cells have been well described on ovarian cancer cells, where modulation of dendritic cells, increasing integrin expression, enhanced matrix metalloproteinase activity, induced TNF-a production and angiogenesis have been observed <ref type="bibr" target="#b35">[35]</ref>.</s><s>SDF-1 and CXCR4 expression might be mechanistically linked to other biomarkers of treatment resistance in HNSCC such as p53 mutation and up-regulation of focal adhesion kinase (FAK) as well as immune markers like PD-L1.</s><s>Importantly in the context of radiation, SDF-1/CXCR4 signalling is involved in radiation-induced infiltration of the tumour by bonemarrow derived immune cells such CD11b positive myelomonocytes which in turn contribute to radiation resistance <ref type="bibr" target="#b36">[36,</ref><ref type="bibr" target="#b37">37]</ref>.</s><s>p53 null mice showed a faster tumour growth associated with increased presence of CD11b positive myeloid-derived suppressor cells and production of SDF-1 <ref type="bibr" target="#b38">[38]</ref>.</s><s>In addition, reduced p53 activity was shown to enhance the migration of multipotent fibroblast-like cells from the bone marrow to the tumour through up-regulation of SDF-1 <ref type="bibr" target="#b39">[39]</ref>.</s><s>In squamous cell carcinomas upregulation of FAK inhibits the anti-tumoral CD8 positive T cell activity through the regulation of the chemokine network <ref type="bibr" target="#b40">[40]</ref>.</s><s>An increased SDF-1 expression in breast cancer cells was shown to stimulate cell adhesion and migration through FAK <ref type="bibr" target="#b41">[41]</ref>.</s><s>In three-dimensional grown human HNSCC FAK overexpression was responsible for an increased radiation resistance through  phosphorylation of AKT and ERK <ref type="bibr" target="#b42">[42]</ref>.</s><s>AKT, together with other intracellular proteins like IP3, mitogen activated protein kinases (MAPKs) and factors as VEGF mediate the SDF-1 activity <ref type="bibr" target="#b7">[8]</ref>.</s><s>Synergistic effects of anti-PD-L1 immunotherapy and SDF-1 targeting support the functional cross-talk between chemokines and CD8 lymphocytes with tumour hypoxia as an important microenvironmental modulator <ref type="bibr" target="#b43">[43,</ref><ref type="bibr" target="#b44">44]</ref>.</s><s>SDF-1 is the only known ligand for CXCR4.</s><s>CXCR4 expression has been demonstrated in many tumour entities, such as breast, ovarian, prostate, melanoma, oesophageal, non-small cell lung cancer, head and neck, bladder, colo-rectal, pancreatic, stomach, sarcoma, leukaemia and glioma <ref type="bibr" target="#b9">[10]</ref>.</s><s>In a meta-analysis of more than five thousand patients affected by different tumour types, Zhao and colleagues demonstrated a shorter progression free survival and overall survival in patients with CXCR4-overexpressing tumours <ref type="bibr" target="#b45">[45]</ref>.</s><s>Data suggest, that CXCR4 expression could be indicative of cancer stem cell (CSC) characteristics <ref type="bibr" target="#b15">[16]</ref>.</s><s>In gliomas, SDF-1/CXCR4 have been found to be overexpressed in perihypoxic tumour areas and, particularly CXCR4, in glioma stem cells, conferring characteristics of aggressiveness and resistance to RT-CT induced apoptosis <ref type="bibr" target="#b46">[46]</ref>.</s><s>Analysing HNSCC cell lines, Faber and colleagues observed an increased formation of podia (key structures for cell adhesion) in CD44, a putative CSC marker, and CXCR4 positive cells under the influence of SDF-1, suggesting that the SDF-1-CXCR4 pathway may be important for the interaction between CSCs and their supportive cells in the CSC niche <ref type="bibr" target="#b13">[14]</ref>.</s><s>In tumour specimen of patients with HNSCC, the same authors showed that CD44 is mainly located on the membrane of cells at the invasive tumour front and that CXCR4 and SDF-1 are located in the membrane and in the cytoplasm of the tumour cells <ref type="bibr" target="#b12">[13]</ref>.</s><s>Similarly, we observed a membrane and an intracellular (mainly cytoplasmic but also nuclear) type of staining for SDF-1 and CXCR4.</s><s>Interestingly, we did not find any correlation between the membrane expression and the outcome, that might suggest a possible role of SDF-1/CXCR4 after its internalization in the cell cytoplasm and translocation to the nucleus.</s><s>However, the significance of the SDF-1/CXCR4 subcellular location remains a matter of debate.</s><s>Some studies conducted on patients with colorectal cancer indicated a negative correlation between the nuclear expression and the clinical outcome <ref type="bibr" target="#b47">[47]</ref><ref type="bibr" target="#b48">[48]</ref><ref type="bibr" target="#b49">[49]</ref>, whereas others studies showed a positive correlation for the nuclear staining but a negative correlation for the cytomembrane staining and the clinical outcome in patients with lung cancer <ref type="bibr" target="#b50">[50,</ref><ref type="bibr" target="#b51">51]</ref>.</s><s>The importance of SDF-1/CXCR4 signalling is supported by in vitro and in vivo experiments including HNSCC models using CXCR4 targeting approaches.</s><s>These experiments showed a decreased cell proliferation, motility, invasion and a reduced metastatic potential under treatment with AMD3100, a pharmacological antagonist of CXCR4 listed under pubchem CID 65015 <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b52">52,</ref><ref type="bibr" target="#b53">53]</ref>.</s><s>Importantly, in preclinical experiments CXCR4 blockade also enhanced radiation response in xenografted breast, lung and glioblastoma tumours indicating that SDF-1/CXCR4 influences tumour radiation sensitivity <ref type="bibr" target="#b36">[36,</ref><ref type="bibr" target="#b54">54,</ref><ref type="bibr" target="#b55">55]</ref>.</s><s>In addition, in glioblastoma SDF-1 is involved in the radiation-induced migratory phenotype <ref type="bibr" target="#b56">[56]</ref>.</s><s>Collectively, the preclinical and clinical data support the concept that the SDF-1/CXCR4 axis contributes to radiation resistance through the mechanistic links to stemness, hypoxia, infiltration by immune cells, intracellular signalling and migration.</s></p><p><s>The prognostic value of SDF-1 and CRCXR4 in HNSCC patients has been reported before from different studies.</s><s>High SDF-1/CXCR4 expression in lymphnode metastases from 30 patients is associated with poor OS <ref type="bibr" target="#b20">[21]</ref>.</s><s>In 47 tumour samples from patients who underwent surgery for HNSCC of the mobile tongue, high CXCR4 expression correlated with T and N stage and is associated with poor OS in the univariate but not in multivariate analysis <ref type="bibr" target="#b31">[32]</ref>.</s><s>In contrast, SDF-1 does not correlate with OS.</s><s>Regarding the latter, the apparent difference to the study reported here is that in the study of Albert et al. <ref type="bibr" target="#b31">[32]</ref> also earlier tumour stages were included which are likely managed with surgery alone.</s><s>In a retrospective analysis of 56 patients with tumours of the oral cavity stage I to IV treated with either neoadjuvant RT-CT, surgery or RT alone, CXCR4 expression has been found to be associated with poor OS and disease specific survival in univariate and multivariate analyses <ref type="bibr" target="#b19">[20]</ref>.</s><s>The discrepancy with our results may be explained by differences in stage distribution and therapeutic It may be speculated that CXCR4 has a specific role in oral cavity tumours, which represent only 27.9% in our study.</s><s>In a large study on 233 HNSCC patients with inoperable tumours undergoing primary RT/RT-CT CXCR4 expression was associated with increased risk of distant metastasis but not with LRC or OS <ref type="bibr" target="#b57">[57]</ref>.</s><s>High SDF-1 expression was associated with better OS.</s><s>However, in multivariate analysis SDF-1 expression was not significantly correlated with LRC, DMFS or OS.</s><s>Interestingly, discrepant from our findings p16 positive tumours showed on average a higher SDF-1/CXCR4 expression than p16 negative tumours.</s><s>In our study SDF-1 was on average lower in p16 positive tumours and no association between CXCR4 expression and p16 could be found.</s><s>A more complex prognostic pattern for SDF-1 and CXCR4 is suggested from a study on 111 HNSCC patients who were treated with surgery, surgery plus postoperative RT/RT-CT or with primary RT/RT-CT <ref type="bibr" target="#b58">[58]</ref>.</s><s>In addition, Clatot and colleagues <ref type="bibr" target="#b59">[59]</ref> found that lower SDF-1 expression determined by PCR in tumour specimen of 71 HNSCC patients was correlating with worse disease-free survival and cancer specific survival.</s><s>No associations were found for CXCR4.</s><s>Taken together, the published data regarding the prognostic role of SDF-1 and CXCR4 in HNSCC is conflicting and may be explained by heterogeneity in patient and treatment characteristics as well as in methodological differences for determination of SDF-1/CXCR4 expression in the different studies.</s><s>Our study contains a large, more homogenous and well-defined patient group.</s><s>However, also taken into account the semi-quantitative scoring with arbitrary thresholds, our results are exploratory and need validation, which is planned in the currently recruiting prospective HNprädBio study of the DKTK-ROG as well as in a cohort of patients affected by locally advanced HNSCC treated with primary RT-CT (De-Colle et al., submitted).</s><s>In addition, an overall biometry is going to be performed including all promising biomarkers that have been exploratively analysed in the retrospective DKTK-ROG cohorts of patients with locally advanced HNSCC such as hypoxia-associated gene expression, CSC marker expression <ref type="bibr" target="#b60">[60,</ref><ref type="bibr" target="#b61">61]</ref>, CD8-positive tumour-infiltrating lymphocytes <ref type="bibr" target="#b62">[62]</ref>, distinct mutation profiles <ref type="bibr" target="#b63">[63]</ref> as well as SDF-1/CXCR4 in order to develop robust prognostic profiles for patient stratification for individualised therapy.</s></p><p><s>In summary, our exploratory data support further investigations of the SDF-1/CXCR4 axis to stratify HNSCC patients for   biologically individualised RT-CT as well as a potential therapeutic target to overcome treatment resistance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest disclosure</head><p><s>We certify that there is no actual or potential conflict of interest in relation to this article.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>Representative images of SDF-1 immunofluorescent stained tumour sections.</s><s>(A) Membrane staining (score 3).</s><s>(B) Intracellular staining (score 2).</s><s>(C) Negative staining (score 0).</s><s>SDF-1 is shown in green, DAPI in blue.</s><s>Similar staining patterns and intensities were observed for CXCR4.</s><s>Original image magnification: 400Â.</s></p></div></figDesc><graphic coords="4,62.36,488.41,481.93,102.22" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. A-D: Kaplan-Meier curves for locoregional tumour control in all patients (A and C) and patients with HPV16 DNA negative tumours only (B and D) according to the SDF-1 and CXCR4 intracellular expression.</s></p></div></figDesc><graphic coords="7,78.98,248.45,211.23,145.39" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Patients characteristics, SDF-1/CXCR4 expression (A) and treatment details (B) for the 201 patients included in the present study.</s></p></div></figDesc><table><row><cell>Age (years)</cell><cell cols="2">57 (median)</cell><cell></cell><cell cols="2">24 (min)</cell><cell></cell><cell></cell><cell>76 (max)</cell></row><row><cell>(A)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Gender</cell><cell cols="2">Male</cell><cell></cell><cell cols="2">161</cell><cell></cell><cell></cell><cell>80,1%</cell></row><row><cell></cell><cell cols="2">Female</cell><cell></cell><cell cols="2">40</cell><cell></cell><cell></cell><cell>19,9%</cell></row><row><cell>Site</cell><cell cols="2">Oral cavity</cell><cell></cell><cell cols="2">56</cell><cell></cell><cell></cell><cell>27,9%</cell></row><row><cell></cell><cell cols="2">Oropharynx</cell><cell></cell><cell cols="2">116</cell><cell></cell><cell></cell><cell>57,7%</cell></row><row><cell></cell><cell cols="2">Hypopharynx</cell><cell></cell><cell cols="2">29</cell><cell></cell><cell></cell><cell>14,4%</cell></row><row><cell>pT stage</cell><cell>T1</cell><cell></cell><cell></cell><cell cols="2">34</cell><cell></cell><cell></cell><cell>16,9%</cell></row><row><cell></cell><cell>T2</cell><cell></cell><cell></cell><cell cols="2">92</cell><cell></cell><cell></cell><cell>45,8%</cell></row><row><cell></cell><cell>T3</cell><cell></cell><cell></cell><cell cols="2">45</cell><cell></cell><cell></cell><cell>22,4%</cell></row><row><cell></cell><cell>T4</cell><cell></cell><cell></cell><cell cols="2">30</cell><cell></cell><cell></cell><cell>14,9%</cell></row><row><cell>R status</cell><cell cols="2">Negative</cell><cell></cell><cell cols="2">113</cell><cell></cell><cell></cell><cell>56,2%</cell></row><row><cell></cell><cell cols="2">Positive</cell><cell></cell><cell cols="2">87</cell><cell></cell><cell></cell><cell>43,3%</cell></row><row><cell></cell><cell cols="2">Unknown</cell><cell></cell><cell>1</cell><cell></cell><cell></cell><cell></cell><cell>0,5%</cell></row><row><cell>ECE</cell><cell cols="2">Negative</cell><cell></cell><cell cols="2">95</cell><cell></cell><cell></cell><cell>47,3%</cell></row><row><cell></cell><cell cols="2">Positive</cell><cell></cell><cell cols="2">106</cell><cell></cell><cell></cell><cell>52,7%</cell></row><row><cell>p16</cell><cell cols="2">Negative</cell><cell></cell><cell cols="2">121</cell><cell></cell><cell></cell><cell>60,2%</cell></row><row><cell></cell><cell cols="2">Positive</cell><cell></cell><cell cols="2">75</cell><cell></cell><cell></cell><cell>37,3%</cell></row><row><cell></cell><cell cols="2">Unknown</cell><cell></cell><cell>5</cell><cell></cell><cell></cell><cell></cell><cell>2,5%</cell></row><row><cell>HPV16 DNA</cell><cell cols="2">Negative</cell><cell></cell><cell cols="2">134</cell><cell></cell><cell></cell><cell>66,7%</cell></row><row><cell></cell><cell cols="2">Positive</cell><cell></cell><cell cols="2">67</cell><cell></cell><cell></cell><cell>33,3%</cell></row><row><cell>icSDF1</cell><cell cols="2">Negative</cell><cell></cell><cell cols="2">148</cell><cell></cell><cell></cell><cell>73,6%</cell></row><row><cell></cell><cell cols="2">Positive</cell><cell></cell><cell cols="2">53</cell><cell></cell><cell></cell><cell>26,4%</cell></row><row><cell>icCXCR4</cell><cell cols="2">Negative</cell><cell></cell><cell cols="2">135</cell><cell></cell><cell></cell><cell>67,2%</cell></row><row><cell></cell><cell cols="2">Positive</cell><cell></cell><cell cols="2">55</cell><cell></cell><cell></cell><cell>27,4%</cell></row><row><cell></cell><cell cols="2">Missing</cell><cell></cell><cell cols="2">11</cell><cell></cell><cell></cell><cell>5,5%</cell></row><row><cell>mSDF1</cell><cell cols="2">Negative</cell><cell></cell><cell cols="2">177</cell><cell></cell><cell></cell><cell>88,1%</cell></row><row><cell></cell><cell cols="2">Positive</cell><cell></cell><cell cols="2">24</cell><cell></cell><cell></cell><cell>11,9%</cell></row><row><cell>mCXCR4</cell><cell cols="2">Negative</cell><cell></cell><cell cols="2">176</cell><cell></cell><cell></cell><cell>87,6%</cell></row><row><cell></cell><cell cols="2">Positive</cell><cell></cell><cell cols="2">14</cell><cell></cell><cell></cell><cell>7,0%</cell></row><row><cell></cell><cell cols="2">Missing</cell><cell></cell><cell cols="2">11</cell><cell></cell><cell></cell><cell>5,5%</cell></row><row><cell></cell><cell></cell><cell>Median</cell><cell>Percentiles</cell><cell></cell><cell></cell><cell></cell><cell>Range</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>10%</cell><cell>25%</cell><cell>75%</cell><cell>90%</cell><cell>Min</cell><cell>Max</cell></row><row><cell>(B)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cisplatin dose (mg/m 2 )</cell><cell></cell><cell>200</cell><cell>100</cell><cell>200</cell><cell>200</cell><cell>240</cell><cell>100</cell><cell>300</cell></row><row><cell>RT dose (Gy)</cell><cell>Boost volume</cell><cell>64,0</cell><cell>60,0</cell><cell>63,8</cell><cell>66,0</cell><cell>66,0</cell><cell>56,0</cell><cell>68,4</cell></row><row><cell></cell><cell>Per fraction</cell><cell>2,0</cell><cell>1,8</cell><cell>2,0</cell><cell>2,0</cell><cell>2,1</cell><cell>1,8</cell><cell>2,2</cell></row><row><cell></cell><cell>Adjuvant volume</cell><cell>50,4</cell><cell>50,0</cell><cell>50,0</cell><cell>55,8</cell><cell>60,0</cell><cell>46,8</cell><cell>66</cell></row><row><cell></cell><cell>Per fraction</cell><cell>2,0</cell><cell>1,8</cell><cell>1,8</cell><cell>2,0</cell><cell>2,0</cell><cell>1,8</cell><cell>2,1</cell></row><row><cell cols="2">Time between surgery and RCT (weeks)</cell><cell>6,0</cell><cell>4,6</cell><cell>5,1</cell><cell>7,6</cell><cell>9,6</cell><cell>0,6</cell><cell>22,9</cell></row><row><cell cols="2">Overall treatment time of RCT (days)</cell><cell>44,0</cell><cell>41,0</cell><cell>43,0</cell><cell>47,0</cell><cell>51,0</cell><cell>31,0</cell><cell>57,0</cell></row><row><cell>Follow-up time (months)</cell><cell></cell><cell>46,2</cell><cell>9,7</cell><cell>30,1</cell><cell>60,5</cell><cell>70,4</cell><cell>2,5</cell><cell>100,1</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Clinico-pathological characteristics and icSDF-1/icCXCR4 expression.</s><s>P-values for comparisons using the Fischer's exact test, significant p-values in bold.</s></p></div></figDesc><table><row><cell></cell><cell>icSDF1 pos.</cell><cell></cell><cell>icSDF1 neg.</cell><cell></cell><cell>p</cell><cell>icCXCR4 pos.</cell><cell></cell><cell>icCXCR4 neg.</cell><cell></cell><cell>p</cell></row><row><cell>Age</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>&lt;Median (57 y)</cell><cell>23</cell><cell>43%</cell><cell>75</cell><cell>51%</cell><cell>0,42</cell><cell>30</cell><cell>55%</cell><cell>65</cell><cell>48%</cell><cell>0,52</cell></row><row><cell>!Median</cell><cell>30</cell><cell>57%</cell><cell>73</cell><cell>49%</cell><cell></cell><cell>25</cell><cell>45%</cell><cell>70</cell><cell>52%</cell><cell></cell></row><row><cell>Gender</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>M</cell><cell>43</cell><cell>81%</cell><cell>118</cell><cell>80%</cell><cell>1,00</cell><cell>42</cell><cell>76%</cell><cell>110</cell><cell>81%</cell><cell>0,43</cell></row><row><cell>F</cell><cell>10</cell><cell>19%</cell><cell>30</cell><cell>20%</cell><cell></cell><cell>13</cell><cell>24%</cell><cell>25</cell><cell>19%</cell><cell></cell></row><row><cell>Site</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Oral cavity</cell><cell>18</cell><cell>34%</cell><cell>38</cell><cell>26%</cell><cell>0,31</cell><cell>19</cell><cell>35%</cell><cell>34</cell><cell>25%</cell><cell>0,41</cell></row><row><cell>Oropharynx</cell><cell>26</cell><cell>49%</cell><cell>90</cell><cell>61%</cell><cell></cell><cell>29</cell><cell>53%</cell><cell>82</cell><cell>61%</cell><cell></cell></row><row><cell>Hypopharynx</cell><cell>9</cell><cell>17%</cell><cell>20</cell><cell>14%</cell><cell></cell><cell>7</cell><cell>13%</cell><cell>19</cell><cell>14%</cell><cell></cell></row><row><cell>pT stage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pT1-2</cell><cell>33</cell><cell>62%</cell><cell>93</cell><cell>63%</cell><cell>1,00</cell><cell>27</cell><cell>49%</cell><cell>89</cell><cell>66%</cell><cell>0,03</cell></row><row><cell>pT3-4</cell><cell>20</cell><cell>38%</cell><cell>55</cell><cell>37%</cell><cell></cell><cell>28</cell><cell>51%</cell><cell>46</cell><cell>34%</cell><cell></cell></row><row><cell>pN stage</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>pN0-1</cell><cell>12</cell><cell>23%</cell><cell>38</cell><cell>26%</cell><cell>0,71</cell><cell>12</cell><cell>22%</cell><cell>36</cell><cell>27%</cell><cell>0,58</cell></row><row><cell>pN2-3</cell><cell>41</cell><cell>77%</cell><cell>110</cell><cell>74%</cell><cell></cell><cell>43</cell><cell>78%</cell><cell>99</cell><cell>73%</cell><cell></cell></row><row><cell>Grading (3 missing)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>G1</cell><cell>0</cell><cell>0%</cell><cell>5</cell><cell>3%</cell><cell>0,01</cell><cell>2</cell><cell>4%</cell><cell>3</cell><cell>2%</cell><cell>0,08</cell></row><row><cell>G2</cell><cell>38</cell><cell>73%</cell><cell>75</cell><cell>51%</cell><cell></cell><cell>37</cell><cell>69%</cell><cell>71</cell><cell>53%</cell><cell></cell></row><row><cell>G3</cell><cell>14</cell><cell>27%</cell><cell>66</cell><cell>45%</cell><cell></cell><cell>15</cell><cell>28%</cell><cell>59</cell><cell>44%</cell><cell></cell></row><row><cell cols="2">Resection margin (1 missing)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>R0</cell><cell>32</cell><cell>62%</cell><cell>81</cell><cell>55%</cell><cell>0,42</cell><cell>32</cell><cell>59%</cell><cell>73</cell><cell>54%</cell><cell>0,63</cell></row><row><cell>R1</cell><cell>20</cell><cell>38%</cell><cell>67</cell><cell>45%</cell><cell></cell><cell>22</cell><cell>41%</cell><cell>62</cell><cell>46%</cell><cell></cell></row><row><cell>ECE</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>25</cell><cell>47%</cell><cell>70</cell><cell>47%</cell><cell>1,00</cell><cell>22</cell><cell>40%</cell><cell>66</cell><cell>49%</cell><cell>0,34</cell></row><row><cell>Yes</cell><cell>28</cell><cell>53%</cell><cell>78</cell><cell>53%</cell><cell></cell><cell>33</cell><cell>60%</cell><cell>69</cell><cell>51%</cell><cell></cell></row><row><cell>HPV16 DNA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>41</cell><cell>77%</cell><cell>93</cell><cell>63%</cell><cell>0,06</cell><cell>40</cell><cell>73%</cell><cell>88</cell><cell>65%</cell><cell>0,39</cell></row><row><cell>Positive</cell><cell>12</cell><cell>23%</cell><cell>55</cell><cell>37%</cell><cell></cell><cell>15</cell><cell>27%</cell><cell>47</cell><cell>35%</cell><cell></cell></row><row><cell>p16 (5/4 missing)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Negative</cell><cell>39</cell><cell>76%</cell><cell>82</cell><cell>57%</cell><cell>0,01</cell><cell>37</cell><cell>69%</cell><cell>78</cell><cell>59%</cell><cell>0,25</cell></row><row><cell>Positive</cell><cell>12</cell><cell>24%</cell><cell>63</cell><cell>43%</cell><cell></cell><cell>17</cell><cell>31%</cell><cell>54</cell><cell>41%</cell><cell></cell></row><row><cell cols="2">Smoking (69/67 missing)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>27</cell><cell>84%</cell><cell>90</cell><cell>90%</cell><cell>0,36</cell><cell>29</cell><cell>85%</cell><cell>80</cell><cell>90%</cell><cell>0,53</cell></row><row><cell>No (never)</cell><cell>5</cell><cell>16%</cell><cell>10</cell><cell>10%</cell><cell></cell><cell>5</cell><cell>15%</cell><cell>9</cell><cell>10%</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Univariate analysis in A: all patients and B: patients with HPV16 DNA negative tumours only.</s><s>Significant results in bold.</s></p></div></figDesc><table><row><cell></cell><cell>LRC</cell><cell></cell><cell></cell><cell></cell><cell>DM</cell><cell></cell><cell></cell><cell></cell><cell>OS</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>HR</cell><cell>CI lower</cell><cell>CI upper</cell><cell>p</cell><cell>HR</cell><cell>CI lower</cell><cell>CI upper</cell><cell>p</cell><cell>HR</cell><cell>CI lower</cell><cell>CI upper</cell><cell>p</cell></row><row><cell>(A) N = 201 (all patients)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age (&lt;Median 57 y vs. !Median)</cell><cell>2,68</cell><cell>1,21</cell><cell>5,91</cell><cell>0,015</cell><cell>1,39</cell><cell>0,73</cell><cell>2,64</cell><cell>0,310</cell><cell>1,43</cell><cell>0,87</cell><cell>2,35</cell><cell>0,158</cell></row><row><cell>Gender (M vs. F)</cell><cell>0,62</cell><cell>0,27</cell><cell>1,39</cell><cell>0,242</cell><cell>1,66</cell><cell>0,65</cell><cell>4,26</cell><cell>0,289</cell><cell>0,80</cell><cell>0,45</cell><cell>1,43</cell><cell>0,446</cell></row><row><cell>Tumour Site (OP vs. OC+HP)</cell><cell>0,37</cell><cell>0,17</cell><cell>0,77</cell><cell>0,009</cell><cell>0,34</cell><cell>0,17</cell><cell>0,66</cell><cell>0,001</cell><cell>0,55</cell><cell>0,34</cell><cell>0,90</cell><cell>0,017</cell></row><row><cell>pT stage (pT3-4 vs. pT1-2)</cell><cell>2,75</cell><cell>1,32</cell><cell>5,75</cell><cell>0,007</cell><cell>2,24</cell><cell>1,18</cell><cell>4,24</cell><cell>0,013</cell><cell>2,48</cell><cell>1,51</cell><cell>4,05</cell><cell>0,000</cell></row><row><cell>pN stage (pN 2-3 vs. pN 0-1)</cell><cell>1,33</cell><cell>0,54</cell><cell>3,28</cell><cell>0,532</cell><cell>3,02</cell><cell>1,07</cell><cell>8,52</cell><cell>0,036</cell><cell>1,10</cell><cell>0,62</cell><cell>1,93</cell><cell>0,752</cell></row><row><cell>Grading (G1 vs. G2 vs. G3)</cell><cell>0,57</cell><cell>0,28</cell><cell>1,16</cell><cell>0,121</cell><cell>0,92</cell><cell>0,51</cell><cell>1,69</cell><cell>0,793</cell><cell>0,75</cell><cell>0,47</cell><cell>1,21</cell><cell>0,240</cell></row><row><cell>Resection margin (R1 vs. R0)</cell><cell>1,07</cell><cell>0,51</cell><cell>2,22</cell><cell>0,867</cell><cell>1,09</cell><cell>0,57</cell><cell>2,06</cell><cell>0,797</cell><cell>1,12</cell><cell>0,68</cell><cell>1,83</cell><cell>0,655</cell></row><row><cell>ECE (yes vs. no)</cell><cell>1,63</cell><cell>0,77</cell><cell>3,46</cell><cell>0,203</cell><cell>2,49</cell><cell>1,19</cell><cell>4,86</cell><cell>0,014</cell><cell>1,70</cell><cell>1,03</cell><cell>2,83</cell><cell>0,040</cell></row><row><cell>p16 (pos. vs. neg.)</cell><cell>0,22</cell><cell>0,08</cell><cell>0,62</cell><cell>0,005</cell><cell>0,21</cell><cell>0,08</cell><cell>0,53</cell><cell>0,001</cell><cell>0,34</cell><cell>0,19</cell><cell>0,63</cell><cell>0,001</cell></row><row><cell>HPV16 DNA (pos. vs. neg.)</cell><cell>0,13</cell><cell>0,03</cell><cell>0,54</cell><cell>0,005</cell><cell>0,38</cell><cell>0,17</cell><cell>0,87</cell><cell>0,024</cell><cell>0,31</cell><cell>0,16</cell><cell>0,61</cell><cell>0,001</cell></row><row><cell>Smoking (yes vs. never)</cell><cell>1,53</cell><cell>0,36</cell><cell>6,62</cell><cell>0,566</cell><cell>4,13</cell><cell>0,56</cell><cell>30,47</cell><cell>0,164</cell><cell>2,57</cell><cell>0,79</cell><cell>8,34</cell><cell>0,115</cell></row><row><cell>mSDF1 (pos. vs. neg.)</cell><cell>0,81</cell><cell>0,25</cell><cell>2,68</cell><cell>0,729</cell><cell>1,28</cell><cell>0,54</cell><cell>3,07</cell><cell>0,578</cell><cell>0,82</cell><cell>0,37</cell><cell>1,80</cell><cell>0,623</cell></row><row><cell>mCXCR4 (pos. vs. neg.)</cell><cell>2,13</cell><cell>0,74</cell><cell>6,14</cell><cell>0,162</cell><cell>1,10</cell><cell>0,34</cell><cell>3,59</cell><cell>0,871</cell><cell>1,72</cell><cell>0,78</cell><cell>3,78</cell><cell>0,180</cell></row><row><cell>icSDF1 (pos. vs. neg.)</cell><cell>2,67</cell><cell>1,29</cell><cell>5,54</cell><cell>0,008</cell><cell>1,02</cell><cell>0,50</cell><cell>2,10</cell><cell>0,955</cell><cell>1,17</cell><cell>0,69</cell><cell>2,01</cell><cell>0,561</cell></row><row><cell>icCXCR4 (pos. vs. neg.)</cell><cell>2,02</cell><cell>0,97</cell><cell>4,21</cell><cell>0,059</cell><cell>1,07</cell><cell>0,53</cell><cell>2,16</cell><cell>0,856</cell><cell>1,26</cell><cell>0,75</cell><cell>2,13</cell><cell>0,384</cell></row><row><cell>icSDF1+icCXCR4 (pos. vs. neg.)</cell><cell>2,87</cell><cell>1,30</cell><cell>6,29</cell><cell>0,009</cell><cell>0,77</cell><cell>0,27</cell><cell>2,15</cell><cell>0,606</cell><cell>1,15</cell><cell>0,59</cell><cell>2,27</cell><cell>0,681</cell></row><row><cell>(B) N = 134 (HPV16 neg. patients)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age (&lt;Median 57 y vs. !Median)</cell><cell>2,38</cell><cell>1,06</cell><cell>5,34</cell><cell>0,035</cell><cell>1,31</cell><cell>0,65</cell><cell>2,66</cell><cell>0,453</cell><cell>1,44</cell><cell>0,84</cell><cell>2,49</cell><cell>0,187</cell></row><row><cell>Gender (M vs. F)</cell><cell>0,63</cell><cell>0,28</cell><cell>1,45</cell><cell>0,277</cell><cell>1,98</cell><cell>0,69</cell><cell>5,65</cell><cell>0,204</cell><cell>0,90</cell><cell>0,48</cell><cell>1,69</cell><cell>0,754</cell></row><row><cell>Tumour Site (OP vs. OC+HP)</cell><cell>0,68</cell><cell>0,31</cell><cell>1,48</cell><cell>0,327</cell><cell>0,53</cell><cell>0,25</cell><cell>1,13</cell><cell>0,102</cell><cell>0,86</cell><cell>0,50</cell><cell>1,47</cell><cell>0,572</cell></row><row><cell>pT stage (pT3-4 vs. pT1-2)</cell><cell>2,69</cell><cell>1,24</cell><cell>5,81</cell><cell>0,012</cell><cell>1,95</cell><cell>0,96</cell><cell>3,97</cell><cell>0,063</cell><cell>2,05</cell><cell>1,20</cell><cell>3,51</cell><cell>0,009</cell></row><row><cell>pN stage (pN 2-3 vs. pN 0-1)</cell><cell>1,46</cell><cell>0,59</cell><cell>3,62</cell><cell>0,417</cell><cell>3,94</cell><cell>1,20</cell><cell>12,96</cell><cell>0,024</cell><cell>1,38</cell><cell>0,74</cell><cell>2,58</cell><cell>0,313</cell></row><row><cell>Grading (G1 vs. G2 vs. G3)</cell><cell>0,68</cell><cell>0,32</cell><cell>1,45</cell><cell>0,321</cell><cell>0,93</cell><cell>0,47</cell><cell>1,86</cell><cell>0,837</cell><cell>0,62</cell><cell>0,36</cell><cell>1,06</cell><cell>0,081</cell></row><row><cell>Resection margin (R1 vs. R0)</cell><cell>1,16</cell><cell>0,54</cell><cell>2,48</cell><cell>0,702</cell><cell>1,07</cell><cell>0,53</cell><cell>2,17</cell><cell>0,858</cell><cell>1,03</cell><cell>0,60</cell><cell>1,75</cell><cell>0,925</cell></row><row><cell>ECE (yes vs. no)</cell><cell>1,62</cell><cell>0,75</cell><cell>3,50</cell><cell>0,223</cell><cell>2,63</cell><cell>1,21</cell><cell>5,71</cell><cell>0,015</cell><cell>1,94</cell><cell>1,11</cell><cell>3,37</cell><cell>0,019</cell></row><row><cell>Smoking (yes vs. never)</cell><cell>0,89</cell><cell>0,20</cell><cell>3,93</cell><cell>0,874</cell><cell cols="3">Cox PH model did not converge</cell><cell></cell><cell>2,15</cell><cell>0,50</cell><cell>9,29</cell><cell>0,303</cell></row><row><cell>mSDF1 (pos. vs. neg.)</cell><cell>0,96</cell><cell>0,23</cell><cell>4,04</cell><cell>0,950</cell><cell>1,69</cell><cell>0,59</cell><cell>4,83</cell><cell>0,329</cell><cell>0,93</cell><cell>0,34</cell><cell>2,59</cell><cell>0,897</cell></row><row><cell>mCXCR4 (pos. vs. neg.)</cell><cell>1,24</cell><cell>0,37</cell><cell>4,14</cell><cell>0,722</cell><cell>1,03</cell><cell>0,31</cell><cell>3,39</cell><cell>0,963</cell><cell>1,24</cell><cell>0,53</cell><cell>2,90</cell><cell>0,622</cell></row><row><cell>icSDF1 (pos. vs. neg.)</cell><cell>2,54</cell><cell>1,19</cell><cell>5,40</cell><cell>0,016</cell><cell>0,94</cell><cell>0,43</cell><cell>2,05</cell><cell>0,883</cell><cell>1,11</cell><cell>0,63</cell><cell>1,95</cell><cell>0,729</cell></row><row><cell>icCXCR4 (pos. vs. neg.)</cell><cell>2,04</cell><cell>0,96</cell><cell>4,33</cell><cell>0,065</cell><cell>1,13</cell><cell>0,53</cell><cell>2,41</cell><cell>0,757</cell><cell>1,27</cell><cell>0,73</cell><cell>2,20</cell><cell>0,405</cell></row><row><cell>icSDF1+icCXCR4 (pos. vs. neg.)</cell><cell>2,52</cell><cell>1,13</cell><cell>5,60</cell><cell>0,024</cell><cell>0,76</cell><cell>0,26</cell><cell>2,17</cell><cell>0,605</cell><cell>1,04</cell><cell>0,52</cell><cell>2,07</cell><cell>0,910</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Multivariate analysis in A: all the patients and B: patients with HPV16 DNA negative tumours only.</s><s>Significant results in bold.</s></p></div></figDesc><table><row><cell></cell><cell>LRC</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>HR</cell><cell>CI lower</cell><cell>CI upper</cell><cell>p</cell></row><row><cell>(A) N = 201 (all patients)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age (&lt;Median 57 y vs. !Median)</cell><cell>3,33</cell><cell>1,48</cell><cell>7,47</cell><cell>0,004</cell></row><row><cell>Tumour Site (OP vs. OC+HP)</cell><cell>0,63</cell><cell>0,29</cell><cell>1,38</cell><cell>0,246</cell></row><row><cell>pT stage (pT3-4 vs. pT1-2)</cell><cell>2,28</cell><cell>1,08</cell><cell>4,81</cell><cell>0,031</cell></row><row><cell>HPV16 DNA (pos. vs. neg.)</cell><cell>0,20</cell><cell>0,04</cell><cell>0,87</cell><cell>0,032</cell></row><row><cell>icSDF1 (pos. vs. neg.)</cell><cell>2,72</cell><cell>1,24</cell><cell>5,93</cell><cell>0,012</cell></row><row><cell>icCXCR4 (pos. vs. neg.)</cell><cell>1,13</cell><cell>0,52</cell><cell>2,46</cell><cell>0,764</cell></row><row><cell>Age (&lt;Median 57 y vs. !Median)</cell><cell>3,33</cell><cell>1,48</cell><cell>7,50</cell><cell>0,004</cell></row><row><cell>Tumour Site (OP vs. OC+HP)</cell><cell>0,64</cell><cell>0,29</cell><cell>1,42</cell><cell>0,273</cell></row><row><cell>pT stage (pT3-4 vs. pT1-2)</cell><cell>2,31</cell><cell>1,09</cell><cell>4,88</cell><cell>0,028</cell></row><row><cell>HPV16 DNA (pos. vs. neg.)</cell><cell>0,19</cell><cell>0,04</cell><cell>0,86</cell><cell>0,031</cell></row><row><cell>icSDF1+icCXCR4 (pos. vs. neg.)</cell><cell>2,66</cell><cell>1,18</cell><cell>6,01</cell><cell>0,018</cell></row><row><cell>(B) N = 134 (HPV16 DNA neg. patients)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age (&lt;Median 57 y vs. !Median)</cell><cell>3,12</cell><cell>1,37</cell><cell>7,13</cell><cell>0,007</cell></row><row><cell>Tumour Site (OP vs. OC+HP)</cell><cell>0,70</cell><cell>0,32</cell><cell>1,56</cell><cell>0,386</cell></row><row><cell>pT stage (pT3-4 vs. pT1-2)</cell><cell>2,45</cell><cell>1,12</cell><cell>5,35</cell><cell>0,025</cell></row><row><cell>icSDF1</cell><cell>2,99</cell><cell>1,33</cell><cell>6,75</cell><cell>0,008</cell></row><row><cell>icCXCR4</cell><cell>1,22</cell><cell>0,55</cell><cell>2,74</cell><cell>0,621</cell></row><row><cell>Age (&lt;Median 57 y vs. !Median)</cell><cell>3,11</cell><cell>1,35</cell><cell>7,14</cell><cell>0,007</cell></row><row><cell>Tumour Site (OP vs. OC+HP)</cell><cell>0,72</cell><cell>0,32</cell><cell>1,59</cell><cell>0,410</cell></row><row><cell>pT stage (pT3-4 vs. pT1-2)</cell><cell>2,51</cell><cell>1,15</cell><cell>5,47</cell><cell>0,021</cell></row><row><cell>icSDF1+icCXCR4</cell><cell>2,87</cell><cell>1,25</cell><cell>6,59</cell><cell>0,013</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">C. De-Colle et al. / Clinical and Translational Radiation Oncology 5 (2017) 28-36</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer statistics</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="7" to="30" />
			<date type="published" when="2017">2017. 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Soerjomataram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dikshit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rebelo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="E359" to="E386" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bernier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Domenge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ozsahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Matuszewska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Lefebvre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Greiner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="1945" to="1952" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Pajak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Forastiere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Saxman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="1937" to="1944" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: results of the German phase III trial ARO 96-3</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fietkau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lautenschlager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dunst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baumann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">5507</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)</title>
		<author>
			<persName><forename type="first">F</forename><surname>Lohaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tinhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Budach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gkika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stuschke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="317" to="323" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Riveiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Halimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hourseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Couvelard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Serova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Head Neck</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1819" to="1828" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Duda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Kozin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Kirkpatrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fukumura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Jain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="2074" to="2080" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cancer and the chemokine network</title>
		<author>
			<persName><forename type="first">F</forename><surname>Balkwill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="540" to="550" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The chemokine system and cancer</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Balkwill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pathol</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page" from="148" to="157" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Chemotaxis in cancer</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Roussos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Condeelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patsialou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="573" to="587" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">CXCR4 expression in prostate cancer progenitor cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dubrovska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Salamone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Telegeev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Stakhovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Schepotin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e31226</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">SDF-1-CXCR4 axis: cell trafficking in the cancer stem cell niche of head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Faber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">R</forename><surname>Goessler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hoermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Schultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Umbreit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stern-Straeter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Rep</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2325" to="2331" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Functional effects of SDF-1alpha on a CD44(+) CXCR4(+) squamous cell carcinoma cell line as a model for interactions in the cancer stem cell niche</title>
		<author>
			<persName><forename type="first">A</forename><surname>Faber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hoermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stern-Straeter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Schultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">R</forename><surname>Goessler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Rep</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="579" to="584" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Rho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">B</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">G</forename><surname>Ko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="209" to="221" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">CXCR4 as biomarker for radioresistant cancer stem cells</title>
		<author>
			<persName><forename type="first">F</forename><surname>Trautmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cojoc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kurth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Melin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Bouchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dubrovska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Biol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="687" to="699" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kurth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mabert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Peitzsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Koi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cojoc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="34494" to="34509" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Carcinogenesis</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1519" to="1527" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakashiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Klosek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shintani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="61" to="66" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Katayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ogino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bandoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nonaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Harabuchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="2937" to="2946" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Involvement of an autocrine stromal cell derived factor-1/CXCR4 system on the distant metastasis of human oral squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Uchida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Onoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tomizuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Begum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Miwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yoshida</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Res</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="685" to="694" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Samara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Chiarelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Valentino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lyubsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zucker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">214</biblScope>
			<biblScope unit="page" from="231" to="241" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">CXCR-4 knockdown by small interfering RNA inhibits cell proliferation and invasion of oral squamous cell carcinoma cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Pai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">O</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Oral Pathol Med</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="214" to="219" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">RNAi targeting CXCR4 inhibits tumor growth through inducing cell cycle arrest and apoptosis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Ther</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="398" to="407" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Cho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="7518" to="7524" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Rehman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oral Sci</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="105" to="118" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Epithelialmesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells</title>
		<author>
			<persName><forename type="first">T</forename><surname>Onoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Uchida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Begum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tomizuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1133" to="1138" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Helman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="161" to="172" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Acquisition of lymph node, but not distant metastatic potentials, by the overexpression of CXCR4 in human oral squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Uchida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Begum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tomizuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Almofti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yoshida</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="1538" to="1546" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The expression of functional chemokine receptor CXCR4 is associated with the metastatic potential of human nasopharyngeal carcinoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="4658" to="4665" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Expression of chemokine receptor CXCR4 is closely correlated with clinical outcome in human nasopharyngeal carcinoma</title>
		<author>
			<persName><forename type="first">H</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="6099" to="6105" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Prognostic value of the chemokine receptor CXCR4 and epithelial-tomesenchymal transition in patients with squamous cell carcinoma of the mobile tongue</title>
		<author>
			<persName><forename type="first">S</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hourseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Halimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Serova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Descatoire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1263" to="1271" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Role of Twist in head and neck carcinoma with lymph node metastasis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Ou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Chien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">I</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1355" to="1359" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">Expression and clinical significance of chemokine receptor 4 in oral squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Gao</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Hua Xi Kou Qiang Yi Xue Za Zhi</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="392" to="395" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Chemokine biology in cancer</title>
		<author>
			<persName><forename type="first">F</forename><surname>Balkwill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Immunol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="49" to="55" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kioi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Harsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="694" to="705" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Tumour-infiltrating CD11b+ myelomonocytes and response to fractionated irradiation of human squamous cell carcinoma (hSCC) xenografts</title>
		<author>
			<persName><forename type="first">K</forename><surname>Zaleska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bruechner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yaromina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="80" to="85" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network</title>
		<author>
			<persName><forename type="first">G</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Marrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Valle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ochoa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1668" to="1675" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Dolfi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Budak-Alpdogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1817" to="1823" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Nuclear FAK controls chemokine transcription, Tregs, and evasion of antitumor immunity</title>
		<author>
			<persName><forename type="first">A</forename><surname>Serrels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Serrels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Byron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Mcpherson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Kriegsheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="160" to="173" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Site-specific metastasis formation: chemokines as regulators of tumor cell adhesion, motility and invasion</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ben-Baruch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Adh Migr</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="328" to="333" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hehlgans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Eke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Cordes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="e669" to="e676" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Semaan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dietrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bergheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dietrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Kalff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Branchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virchows Arch</title>
		<imprint>
			<biblScope unit="volume">470</biblScope>
			<biblScope unit="page" from="185" to="196" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Feig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kraman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Wells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Deonarine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="20212" to="20217" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">CXCR4 over-expression and survival in cancer: a system review and meta-analysis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Weng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="5022" to="5040" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment</title>
		<author>
			<persName><forename type="first">R</forename><surname>Wurth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bajetto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Barbieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Florio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Cell Neurosci</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">144</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Speetjens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Liefers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Korbee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Mesker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Van De Velde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Van Vlierberghe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Microenviron</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Expression of SDF-1 alpha and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Yoshitake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fukui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamagishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sekikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fujii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tomita</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1682" to="1689" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Nuclear expression of CXCR4 is associated with advanced colorectal cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Colorectal Dis</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1185" to="1191" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hyjek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Vazquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Meherally</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Chadwick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Cardiovasc Surg</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="615" to="621" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Otsuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Klimowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kopciuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Petrillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Konno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1169" to="1178" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Emerging targets in cancer management: role of the CXCL12/CXCR4 axis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cojoc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Peitzsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Trautmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Polishchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Telegeev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dubrovska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Onco Targets Ther</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1347" to="1361" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Molecular pathways: targeting the CXCR4-CXCL12 axis-untapped potential in the tumor microenvironment</title>
		<author>
			<persName><forename type="first">S</forename><surname>Scala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="4278" to="4285" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Kozin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Kamoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Duda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="5679" to="5685" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGFbeta-dependent HIF-1alpha-mediated induction of CXCL12</title>
		<author>
			<persName><forename type="first">G</forename><surname>Tabatabai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Frank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mohle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wick</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="2426" to="2435" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">BK K+ channel blockade inhibits radiation-induced migration/brain infiltration of glioblastoma cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Edalat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stegen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klumpp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Haehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schilbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lukowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="14259" to="14278" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rave-Frank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tehrany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Leu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Burfeind</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Strahlenther Onkol</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page" from="47" to="54" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Expression of the CXCL12/CXCR4 chemokine axis predicts regional control in head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">X</forename><surname>Leon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Diez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sumarroca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Arch Otorhinolaryngol</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page" from="4525" to="4533" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">F</forename><surname>Clatot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Picquenot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Choussy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gouerant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Moldovan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schultheis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oral Oncol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1062" to="1068" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV(-) HNSCC after postoperative radiochemotherapy: a multicenter study of the DKTK-ROG</title>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gudziol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nowak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lohaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Von Neubeck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="2639" to="2649" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Löck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Krenn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Appold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lohaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nowak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Radiat Oncol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="19" to="26" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">CD8+ tumourinfiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Balermpas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rodel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rodel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lohaus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="171" to="181" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation</title>
		<author>
			<persName><forename type="first">I</forename><surname>Tinhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Budach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Saki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Konschak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Niehr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Johrens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="78" to="86" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
